Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

NCT06553638 · clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

University Hospital, Brest